HIVE prices US$115M 0% exchangeable senior notes due 2031 (upsized)
AI Summary
HIVE priced US$115 million aggregate principal of 0% exchangeable senior notes due 2031 in a private Rule 144A offering by its Bermuda subsidiary, up from $100M, with an initial purchasers' option to buy up to an additional $15M. The notes are non‑interest bearing, guaranteed by HIVE, exchangeable at 206.9429 shares per $1,000 principal (initial exchange price ≈ $4.83) and the sale is expected to close on June 30, 2026. Estimated net proceeds are ~US$110.0M (≈US$124.5M if the option is exercised) and HIVE entered capped‑call hedges (cap $8.5275) whose hedging activity could involve purchases or sales of HIVE shares. Timing: The press release does not indicate dilution today; initial share dilution occurs at the offering close (Jun 30, 2026), and once the offering closes those shares have been issued.
Positives
- Estimated net proceeds ~US$110.0M (≈US$124.5M if option exercised)
- Capped‑call hedges in place to reduce economic dilution on exchanges
- Private Rule 144A placement to QIBs (limits broad retail issuance at announcement)
Negatives
- Notes are exchangeable into common shares — full $115M would convert to ~23.8M shares (≈26.9M if $130M option exercised)
- Option to upsize by $15M increases potential future share issuance
- Hedging activity by option counterparties/affiliates may involve selling shares and could pressure the stock
Filing Context
Filing and Dilution Context
Earliest dilution
Earliest dilution: Jun 30, 2026 close
Dilution status
delayed
Dilution timing
Dilution status: Delayed
Trigger type
closing
Trigger date
Jun 30, 2026